celecoxib has been researched along with 2019 Novel Coronavirus Disease in 5 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study aimed to evaluate the safety and tolerability of a fixed-dose co-formulation of ciprofloxacin and celecoxib (PrimeC) in patients with amyotrophic lateral sclerosis (ALS), and to examine its effects on disease progression and ALS-related biomarkers." | 5.69 | Combination of ciprofloxacin/celecoxib as a novel therapeutic strategy for ALS. ( Abramovich, B; Beaulieu, D; Berry, JD; Birman, N; Drory, VE; Eitan, E; Elgrart, K; Ennist, DL; Paganoni, S; Pushett, A; Russek-Blum, N; Salomon-Zimri, S; Shefner, JM; Van Eijk, RPA, 2023) |
| "Carprofen and Celecoxib have been selected by the COVID Moonshot initiative for in vitro testing; they show 3." | 1.56 | Prediction of Novel Inhibitors of the Main Protease (M-pro) of SARS-CoV-2 through Consensus Docking and Drug Reposition. ( Cereto-Massagué, A; Garcia-Vallvé, S; Gimeno, A; Macip, G; Mestres-Truyol, J; Ojeda-Montes, MJ; Pujadas, G; Saldivar-Espinoza, B, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 5 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| AlAjmi, MF | 1 |
| Rehman, MT | 1 |
| Hussain, A | 1 |
| Mosquera-Sulbaran, JA | 1 |
| Pedreañez, A | 1 |
| Carrero, Y | 1 |
| Callejas, D | 1 |
| Salomon-Zimri, S | 1 |
| Pushett, A | 1 |
| Russek-Blum, N | 1 |
| Van Eijk, RPA | 1 |
| Birman, N | 1 |
| Abramovich, B | 1 |
| Eitan, E | 1 |
| Elgrart, K | 1 |
| Beaulieu, D | 1 |
| Ennist, DL | 1 |
| Berry, JD | 1 |
| Paganoni, S | 1 |
| Shefner, JM | 1 |
| Drory, VE | 1 |
| Gimeno, A | 1 |
| Mestres-Truyol, J | 1 |
| Ojeda-Montes, MJ | 1 |
| Macip, G | 1 |
| Saldivar-Espinoza, B | 1 |
| Cereto-Massagué, A | 1 |
| Pujadas, G | 1 |
| Garcia-Vallvé, S | 1 |
| Imaduddin, M | 1 |
| Sultania, M | 1 |
| Vigneshwaran, B | 1 |
| Muduly, DK | 1 |
| Kar, M | 1 |
1 review available for celecoxib and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
C-reactive protein as an effector molecule in Covid-19 pathogenesis.
Topics: ADAM17 Protein; Angiotensin-Converting Enzyme 2; Anti-Inflammatory Agents; Biomarkers; C-Reactive Pr | 2021 |
1 trial available for celecoxib and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
Combination of ciprofloxacin/celecoxib as a novel therapeutic strategy for ALS.
Topics: Amyotrophic Lateral Sclerosis; Biomarkers; Celecoxib; Ciprofloxacin; COVID-19; Disease Progression; | 2023 |
3 other studies available for celecoxib and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
Celecoxib, Glipizide, Lapatinib, and Sitagliptin as potential suspects of aggravating SARS-CoV-2 (COVID-19) infection: a computational approach.
Topics: Angiotensin-Converting Enzyme 2; Celecoxib; COVID-19; Glipizide; Humans; Lapatinib; Molecular Dockin | 2022 |
Prediction of Novel Inhibitors of the Main Protease (M-pro) of SARS-CoV-2 through Consensus Docking and Drug Reposition.
Topics: Antiviral Agents; Betacoronavirus; Binding Sites; Carbazoles; Celecoxib; Coronavirus Infections; COV | 2020 |
Metronomic therapy using Methotrexate and Celecoxib: A Boon for Oral Cancer patients during COVID-19 Pandemic.
Topics: Carcinoma; Celecoxib; Cisplatin; COVID-19; Humans; Methotrexate; Mouth Neoplasms; Neoplasm Recurrenc | 2021 |